Pediapharm Inc (CVE:PDP) insider Knight Therapeutics Inc. sold 40,000 shares of the company’s stock in a transaction that occurred on Thursday, August 30th. The shares were sold at an average price of C$0.46, for a total value of C$18,400.00.

Knight Therapeutics Inc. also recently made the following trade(s):

  • On Friday, July 6th, Knight Therapeutics Inc. sold 12,500 shares of Pediapharm stock. The shares were sold at an average price of C$0.46, for a total value of C$5,750.00.
  • On Monday, July 9th, Knight Therapeutics Inc. sold 1,000 shares of Pediapharm stock. The shares were sold at an average price of C$0.46, for a total value of C$460.00.
  • On Wednesday, July 4th, Knight Therapeutics Inc. sold 40,000 shares of Pediapharm stock. The shares were sold at an average price of C$0.46, for a total value of C$18,400.00.

CVE PDP traded down C$0.03 on Friday, reaching C$0.44. The stock had a trading volume of 30,500 shares, compared to its average volume of 106,313. Pediapharm Inc has a 12-month low of C$0.25 and a 12-month high of C$0.49.

Pediapharm (CVE:PDP) last issued its quarterly earnings data on Wednesday, July 18th. The company reported C($0.01) earnings per share for the quarter. Pediapharm had a negative net margin of 10.92% and a negative return on equity of 26.38%. The firm had revenue of C$2.10 million during the quarter.

Pediapharm Company Profile

Pediapharm Inc operates as a specialty pharmaceutical company in Canada. It distributes prescription medicines that are used to treat pathological conditions, which primarily affect children from infancy to 18 years of age; and commercializes non-prescription products, such as non-prescription drugs and medical devices that fulfill unmet medical needs of children.

Recommended Story: Hedge Funds – Risk or Reward?

Receive News & Ratings for Pediapharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pediapharm and related companies with MarketBeat.com's FREE daily email newsletter.